Latest Breaking News On - Remi barbier - Page 2 : comparemela.com

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSouth koreaPuerto ricoRobert anderson jrEric schoenPierre gravierRemi barbierCassava sciences incDrug administrationCity university of new yorkCochin institute parisResearch internationalCompany board of directorsCassava sciencesOrrick herrington sutcliffe

Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial

SAVA stock jumped 9% on Wednesday after Casava Sciences shared promising results of a clinical trial of its Alzheimer's treatment.

Remi barbierCasava sciencesHopeful clinical

Topline results of Phase 3 studies of simufilam for Alzheimer s due this year

Topline results of Phase 3 studies of simufilam for Alzheimer s due this year
alzheimersnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzheimersnewstoday.com Daily Mail and Mail on Sunday newspapers.

Remi barbierCassava sciencesDrug administrationAlzheimer disease cooperative studyTwo phaseDisease assessment scale cognitive subscaleDisease cooperative study activitiesDaily living

No Decline in Cognition Scores in Patients with Mild Alzheimer s Disease Who Received Simufilam Continuously For 24 Months

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam.

United statesPuerto ricoSouth koreaRemi barbierEric schoenSuzanne hendrixCassava sciencesPentara corporationA groupGroup of patientsCassava sciences incNational institutes of healthCog scores were stableMild alzheimerGroup averageSimufilam safe

Cassava Sciences (SAVA) Reports No Decline in Cognition Scores in Simufilam Patients with Mild Alzheimer s Disease at 24 Months

Cassava Sciences (SAVA) Reports No Decline in Cognition Scores in Simufilam Patients with Mild Alzheimer s Disease at 24 Months
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoSouth koreaSuzanne hendrixEric schoenRemi barbierCassava sciencesPentara corporationCassava sciences incNational institutes of healthFull analysis setCognition maintenance studyCassava scienceMore information contactChief financialNote regarding forward looking statements